10.3978/j.issn.1000-9604.2015.07.02
Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide (1).Most patients present with intermediate or advanced disease that is not amenable to curative treatment, and the median survival in this group is 6-8 months (2).Several studies and welldesigned randomized trials have shown a positive effect of transcatheter arterial chemoembolization (TACE) on patient outcome and survival (3-8).As nicely described in the present article from Wáng et al., assessment of tumor response is of extreme importance in patients undergoinglocoregional treatments of liver cancer (9).
curative treatment、positive effect、liver cancer
27
U67;TH7
2016-01-22(万方平台首次上网日期,不代表论文的发表时间)
共6页
611-616